Reuters logo
BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834
November 1, 2017 / 12:38 PM / 2 months ago

BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc

* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)

* Mylan NV - ‍M834, a proposed biosimilar of Orencia (Abatacept), did not meet its primary pharmacokinetic (PK) endpoints in phase 1 study​

* Mylan NV - ‍Momenta And Co continue to gather and analyze data to inform next steps for M834 program ​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below